Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 264 clinical trials
Therapeutic Drug Monitoring of Guselkumab in Psoriasis Patients (BIOLOPTIM-GUS)

Biologic such as guselkumab are currently the most effective treatment option for patients with moderate to severe psoriasis. But they are costly for healthcare systems and still described

psoriasis
  • 1 views
  • 21 Feb, 2022
  • 1 location
Levels of Pigment Epithelium-derived Factor in Patients With Psoriasis.

Psoriasis is an immune-mediated chronic inflammatory skin disease associated with increase interaction of inflammatory mediators like adipokines. Pigment epithelium-derived factor (PEDF) is one

Accepts healthy volunteers
  • 0 views
  • 27 Apr, 2022
  • 1 location
Preventing Arthritis in a Multi-Center Psoriasis At-Risk Cohort (PAMPA)

This is a multi-center (North-America), randomized, double-blind, placebo-controlled, wait-list, interventional, preventive trial of guselkumab in high-risk psoriasis patients compared to non

guselkumab
  • 0 views
  • 25 Oct, 2022
  • 5 locations
Efficacy and Safety of Benvitimod Cream in the Retreatment of Mild to Moderate Psoriasis

mild to moderate stable psoriasis vulgaris in adults. Approximately 390 participants with mild to moderate stable psoriasis vulgaris will be enrolled and randomly divided into two groups in a 2:1 ratio

psoriasis vulgaris
  • 0 views
  • 01 May, 2022
  • 1 location
A Phase 2b, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety and Efficacy of Cedirogant (ABBV-157) in Adult Subjects With Moderate to Severe Psoriasis

Psoriasis is a chronic disease characterized by marked inflammation and thickening of the skin that results in thick, scaly skin plaques. This study will assess how safe and effective cedirogant

systemic therapy
plaque psoriasis
phototherapy
desquamation
  • 6 views
  • 12 Oct, 2022
  • 53 locations
Role of Glucose Metabolism in Migration of Cutaneous Dendritic Cells in Psoriasis

Dendritic cells (DC) paly a key role in the induction and chronicity of psoriasis by capturing the antigenes and activating the T cell repsonse. This activation requires their migration from the

diabetes
plaque psoriasis
  • 0 views
  • 04 Oct, 2022
  • 1 location
Therapeutic Drug Monitoring of Brodalumab in Psoriasis Patients (BIOLOPTIM-BRO) (BIOLOPTIM-BRO)

Biologics, such as brodalumab, are currently the most effective treatment option for patients with moderate-to-severe psoriasis. But they are costly for health care systems and prescribed

biologics
brodalumab
psoriasis
  • 5 views
  • 21 Feb, 2022
  • 1 location
Augmenting Standard-of-care Treatment of Plaque Psoriasis by Neuromodulation

The human body responds to inflammation, such as psoriatic skin lesions, by activating the cholinergic anti-inflammatory pathway. In patients with plaque psoriasis, this pathway is not

  • 0 views
  • 12 May, 2022
  • 1 location
Tapinarof for the Treatment of Plaque Psoriasis in Pediatric Subjects

This is an open-label, multi-center, Phase 3 study to evaluate tapinarof cream, 1% in pediatric subjects with plaque psoriasis.

  • 0 views
  • 15 Mar, 2022
  • 11 locations
A Phase Ⅲ Efficacy and Safety Study of Hemay005 in Subjects With Moderate to Severe Plaque Psoriasis

Hemay005 is a novel phosphodiesterase type 4(PDE4) inhibitor being developed for the treatment of psoriasis. After single asending dose and mutiple asending dose in health subjects. phase 2

plaque psoriasis
  • 0 views
  • 06 Jul, 2022
  • 1 location